文献速递慢病防控与筛查免疫规划

展示CT26新表位的生物工程化ClearColi™来源外膜囊泡作为预防性小鼠结肠癌模型中的强效疫苗佐剂

Bioengineered ClearColi™-derived outer membrane vesicles displaying CT26 neoepitopes as potent vaccine adjuvants against colon carcinoma in a preventive mouse model.
PubMed 文献 · Vaccine · 2025-04-11

研究在BALB/c小鼠中比较CT26多表位疫苗单独或联合OMV、展示CT26多表位的rOMV及铝佐剂的免疫效果。rOMV和OMV佐剂组较铝佐剂组诱导更高的CT26多表位及CT26-M90肽特异性IgG2a抗体、IFN-γ和TNF-α;rOMV佐剂组颗粒酶B水平更高,且较铝佐剂组显著缩小肿瘤体积。

要点

  • rOMV和OMV作为CT26多表位疫苗佐剂可增强Th1偏向的体液与细胞免疫应答。
  • rOMV佐剂组较铝佐剂组诱导更高颗粒酶B水平并显著缩小CT26肿瘤体积。
  • 展示多表位的rOMV或可为个性化癌症疫苗及高变异抗原疫苗提供平台。

核心结论

  • rOMV和OMV作为CT26多表位疫苗佐剂在预防性CT26小鼠模型中有效。

研究设计与样本

  • 在BALB/c小鼠中给予CT26多表位疫苗单独或联合OMV、展示CT26多表位的rOMV及铝佐剂,评估体液免疫、细胞因子及对CT26细胞的预防效果。

主要发现

  • OMV及rOMV佐剂联合CT26多表位组较铝佐剂组产生更高的CT26多表位和CT26-M90肽特异性IgG2a抗体,并增强IFN-γ和TNF-α水平。
  • rOMV佐剂组较铝佐剂组诱导更高水平的颗粒酶B,并显著缩小肿瘤体积。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The mutation frequency of colorectal cancer, the third most diagnosed tumor worldwide, is usually very high. To simultaneously target several mutations, we previously designed a CT26 polytope containing neoepitopes and epitopes of the murine CT26 colon cancer cell line. Additionally, to overcome the low immunogenicity of the CT26 polytope vaccine, we isolated recombinant outer membrane vesicles (rOMVs) displaying CT26 polytope from ClearColi™ and found that they induce antitumor immunity. In light of our previous studies, in this study, the recombinant CT26 polytope was chosen as the antigen to investigate the role of ClearColi™-derived OMVs and rOMVs displaying the CT26 polytope as adjuvants against colorectal carcinoma. CT26 polytope vaccine alone and in combination with OMV, rOMV displaying CT26 polytope, and alum as adjuvants were administered to BALB/c mice. Then, the humoral immunity specific to CT26-M90 and CT26 polytope and the stimulated IFN-γ, TNF-α, IL-10, and granzyme B were evaluated. Furthermore, the preventive effect of different immunization strategies against CT26 cells was assessed. Herein, immunization with OMVs and, particularly, rOMVs as adjuvants in combination with CT26 polytope resulted in higher production of CT26 polytope- and CT26-M90 peptide-specific IgG2a antibodies, an indicator of potential Th1 response, and enhanced levels of IFN-γ and TNF-α compared to alum. Furthermore, rOMVs as adjuvants induced higher levels of granzyme B and protection against CT26 characterized by significant reduction of tumor size compared to alum as adjuvants. This study indicates the efficacy of rOMVs and OMVs as adjuvants in combination with the CT26 polytope in a preventive CT26 mouse model. rOMVs delivering polytopic antigens, including different neoepitopes and epitopes as adjuvants, can provide promising platforms for the development of personalized cancer vaccines and vaccines against diseases containing highly variable antigens.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Sharif E, Mobasheri T, Mohit E, et al. Bioengineered ClearColi™-derived outer membrane vesicles displaying CT26 neoepitopes as potent vaccine adjuvants against colon carcinoma in a preventive mouse model. Vaccine. 2025. PMID: 40209628. doi:10.1016/j.vaccine.2025.127088

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。